Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06418529 · ClinicalTrials.gov registry record
A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
A clinical trial of Rheumatoid Arthritis, sponsored by Pfizer.
- Completed
- Registry status
- 21,340
- Enrollment target
- 1
- Study location
NCT06418529: Completed study of Rheumatoid Arthritis, sponsored by Pfizer.
NCT06418529 is a study of Rheumatoid Arthritis that has completed, run by Pfizer. The registered enrollment target is 21,340 participants, above the 4,582-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (366% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06418529, a study of Rheumatoid Arthritis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 21,340 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling. The study will look at data from a large, US-based group of RA patients who have taken the below medicines: * Tofacitinib * Abatacept * Tocilizumab or sarilumab The study will compare clinical disease activity scores of patients on the different medicines taken. The study will also decide whether some patient traits or disease factors play a role in how medicines may improve disease activity.
Primary Outcome
CDAI is a simplified index for assessing disease activity. CDAI is the numerical sum of 4 outcome parameters: swollen joint counts (SJC) and tender/painful joint counts (TJC) (score range from 0 to 28, higher scores = worse condition), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA) (assessed on 0-10 centimeter \[cm)\] visual analog scale \[VAS\]; higher scores = greater affection due to disease activity). CDAI total score =
Conditions Studied
Interventions
- DRUG abatacept
- DRUG tofacitinib
- DRUG tumor necrosis factor inhibitors (TNFi)
- DRUG tocilizumab or sarilumab
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,340 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2024-07-19 |
What the finished NCT06418529 record still lists
NCT06418529 is an observational study that tracks outcomes without assigning an intervention. Its 21,340 participants enrollment target places it among the larger protocols in the corpus, above the 4,582-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (366% higher).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 4 interventions - of which abatacept is the first listed.
NCT06418529 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06418529 about?
NCT06418529 is a clinical study titled "A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis". The purpose of this study is to learn how different types of medicines may improve disease activity in people with rheumatoid arthritis (RA). RA is a kind of joint disease that causes pain and swelling. The study will look at data from a large, US-based group of RA patients who have taken the below...
What is the current status of trial NCT06418529?
This trial is currently completed. The enrollment target is 21,340 participants. The study started on 2024-05-15. Estimated completion is 2024-07-19.
What conditions does trial NCT06418529 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06418529?
The interventions under investigation include: abatacept (DRUG), tofacitinib (DRUG), tumor necrosis factor inhibitors (TNFi) (DRUG), tocilizumab or sarilumab (DRUG).
Who is sponsoring clinical trial NCT06418529?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06418529 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06418529's enrollment target sits among peer trials
21,340 6th of 197 higher than 192 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
RECRUITING · NA
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Physica System Total Knee Replacement Registry Study
RECRUITING · NA
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06047041 · 21,350 participants · NA
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
- NCT07213531 · 21,000 participants
Enhanced Valves Interventions and Safe AI Generated End Results
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT05488080 · 22,032 participants · NA
PAINED: Project Addressing INequities in the Emergency Department
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI